[Form 4] PTC THERAPEUTICS, INC. Insider Trading Activity

Rhea-AI Filing Summary

PTC Therapeutics director Emma Reeve reported multiple transactions on 10/03/2025 under a written Rule 10b5-1 plan adopted on 03/04/2025. The filings show a mix of purchases and sales in the issuer's common stock and related stock options. Across the trades on that date the reporting person acquired 10,000 shares and additional option grants totaling 25,562 option rights at exercise prices of $33.02 and $33.63, while executing several sales at weighted average prices in the mid-$60s. The director's reported direct beneficial ownership after the transactions is 10,332 shares.

The transactions were effected pursuant to the 10b5-1 plan and several sale prices are disclosed as weighted averages across multiple trades; detailed per-trade price breakdowns are offered on request to regulators or the issuer.

Positive

• Transactions executed under a written Rule 10b5-1 plan adopted on 03/04/2025, providing structured timing for trades
• Acquisition of option rights totaling 25,562 (10,000; 6,912; 8,650) with exercise prices at $33.02 and $33.63, which may align incentives with long-term value

Negative

• Material net reduction in direct common-stock holdings to 10,332 shares after multiple sales on 10/03/2025
• Multiple dispositions executed at weighted average prices in the mid-$60 range, indicating significant share sales the same day options were recorded

Insights

Corporate Governance Expert

TL;DR: A director used a 10b5-1 plan to execute mixed purchases, option activity and multiple stock sales on 10/03/2025.

The pattern shows a director-initiated trading program with both acquisitions and dispositions recorded the same day. The report discloses option rights with exercise prices at $33.02 and $33.63, and common-stock sales executed at weighted average prices in the mid-$60 range. Using a pre-established plan is a standard governance practice to create an affirmative defense under trading rules.

Key dependencies and near-term items to watch include any additional filings amending these transactions and whether the issuer or the director discloses further plan details; the plan adoption date of 03/04/2025 is the monitorable milestone that supports the defense.

Equity Compensation Analyst

TL;DR: The filing records option grants/exercises and purchases that increase option exposure while common shares were sold.

The derivative table shows acquisition of option rights totaling 25,562 option units (10,000 + 6,912 + 8,650) exercisable immediately at the stated prices and currently exercisable. However, the reported number of shares beneficially owned directly after the transactions is reduced to 10,332, reflecting net dispositions in common stock executed the same day. Option strike prices are $33.02 and $33.63, significantly below the sale prices reported.

Monitor whether options are exercised or converted into shares in subsequent filings and any schedule changes around option vesting or additional 10b5-1 plan activity in the coming months.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reeve Emma

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
10/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/03/2025		M(1)		10,000	A	$39.42	20,332	D
Common Stock	10/03/2025		S(1)		3,028	D	$65.09(2)	17,304	D
Common Stock	10/03/2025		S(1)		4,591	D	$66.09(3)	12,713	D
Common Stock	10/03/2025		S(1)		2,381	D	$66.87(4)	10,332	D
Common Stock	10/03/2025		M(1)		6,912	A	$33.02	17,244	D
Common Stock	10/03/2025		S(1)		2,163	D	$65.02(5)	15,081	D
Common Stock	10/03/2025		S(1)		3,149	D	$66.11(6)	11,932	D
Common Stock	10/03/2025		S(1)		1,600	D	$66.93(7)	10,332	D
Common Stock	10/03/2025		M(1)		8,650	A	$33.63	18,982	D
Common Stock	10/03/2025		S(1)		2,729	D	$65.05(8)	16,253	D
Common Stock	10/03/2025		S(1)		4,037	D	$66.1(9)	12,216	D
Common Stock	10/03/2025		S(1)		1,884	D	$66.89(10)	10,332	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$33.63	10/03/2025		M(1)			10,000	(11)	01/04/2033	Common Stock	10,000	$0	0	D
Stock Option (Right to Buy)	$33.02	10/03/2025		M(1)			6,912	(11)	01/21/2029	Common Stock	6,912	$0	0	D
Stock Option (Right to Buy)	$33.63	10/03/2025		M(1)			8,650	(11)	12/13/2028	Common Stock	8,650	$0	0	D

Explanation of Responses:

1. This transaction was effected pursuant to a written Rule 10b5-1 plan adopted by the Reporting Person on March 4, 2025.

2. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

3. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

4. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.50 to $67.29 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

5. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

6. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.48 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

7. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.33 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

8. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $64.50 to $65.49 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

9. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $65.50 to $66.46 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

10. This price represents the weighted average price of sale transactions that were executed in multiple trades at prices ranging from $66.61 to $67.28 per share. The Reporting Person hereby undertakes, upon request by the SEC staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.

11. Currently exercisable.

	/s/ Avraham S. Adler, Attorney-in-Fact	10/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did PTC Therapeutics director Emma Reeve report on Form 4 (PTCT)?

The director reported multiple transactions on 10/03/2025 including purchases, sales and acquisition of stock options under a 10b5-1 plan, leaving 10,332 shares beneficially owned.

Did Emma Reeve use a 10b5-1 trading plan for these transactions?

Yes. The transactions were effected pursuant to a written Rule 10b5-1 plan adopted on 03/04/2025, as stated in the filing.

How many option rights and at what strikes were reported?

The filing shows option rights of 10,000, 6,912, and 8,650 exercisable at $33.63 and $33.02.

What were the sale prices for the common-stock dispositions?

Sales were reported at weighted average prices in ranges mid-$64.50 to $67.33; specific weighted averages per block are disclosed in the filing.

How many shares were acquired outright on the transaction date?

The filing records an acquisition of 10,000 common shares on 10/03/2025.